Locally Advanced or Metastatic Solid Tumor Clinical Trials

26 recruitingLast updated: June 18, 2026

There are 26 actively recruiting locally advanced or metastatic solid tumor clinical trials across 27 countries. Studies span Phase 1, Phase 2. Top locations include Shanghai, Shanghai Municipality, China, Beijing, Beijing Municipality, China, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


Locally Advanced or Metastatic Solid Tumor Trials at a Glance

26 actively recruiting trials for locally advanced or metastatic solid tumor are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 1 with 23 trials, with the heaviest enrollment activity in Shanghai, Beijing, and Guangzhou. Lead sponsors running locally advanced or metastatic solid tumor studies include Sichuan Baili Pharmaceutical Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., and Avistone Biotechnology Co., Ltd..

Browse locally advanced or metastatic solid tumor trials by phase

Treatments under study

About Locally Advanced or Metastatic Solid Tumor Clinical Trials

Looking for clinical trials for Locally Advanced or Metastatic Solid Tumor? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced or Metastatic Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced or Metastatic Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Phase 1

A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors.

Locally Advanced or Metastatic Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.50 enrolled1 locationNCT07607054
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Colorectal, CancerPancreatic CancerGastric Cancer+1 more
ArriVent BioPharma, Inc.405 enrolled20 locationsNCT07066657
Recruiting
Phase 1Phase 2

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Biocity Biopharmaceutics Co., Ltd.111 enrolled1 locationNCT07469774
Recruiting
Phase 1

GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.

Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated
Changchun GeneScience Pharmaceutical Co., Ltd.186 enrolled1 locationNCT07407504
Recruiting
Phase 1

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.63 enrolled15 locationsNCT06307795
Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Bayer150 enrolled76 locationsNCT04142437
Recruiting
Phase 1

Study of XB010 in Subjects With Solid Tumors

Hormone Receptor-Positive Breast CancerLocally Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer(TNBC)+3 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 1

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.96 enrolled5 locationsNCT06716138
Recruiting
Phase 2

A Study of YL202 in Patients With Advanced Solid Tumors

Colorectal, CancerCervical CancerNon-small Cell Lung Cancer+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.100 enrolled1 locationNCT07202364
Recruiting
Phase 1

AZD5305 hADME in Patients With Advanced Solid Malignancies

Locally Advanced or Metastatic Solid Tumor
AstraZeneca8 enrolled2 locationsNCT06713369
Recruiting
Phase 1Phase 2

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Unresectable Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.250 enrolled3 locationsNCT06974812
Recruiting
Phase 2

A Study of YL202 in Selected Patients With Advanced Solid Tumors

Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 1

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.26 enrolled7 locationsNCT05461768
Recruiting
Phase 1

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Locally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.570 enrolled8 locationsNCT05194982
Recruiting
Phase 1

A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.30 enrolled1 locationNCT06349811
Recruiting
Phase 1

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Antengene Therapeutics Limited98 enrolled7 locationsNCT05205109
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Locally Advanced or Metastatic Solid Tumors+1 more
AP Biosciences Inc.168 enrolled1 locationNCT05473156
Recruiting
Phase 1Phase 2

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Pyrotech Therapeutics, Inc.68 enrolled3 locationsNCT06244992
Recruiting
Phase 1Phase 2

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Dong-A ST Co., Ltd.125 enrolled2 locationsNCT06293651